Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $110.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 45.14% year-over-year to $110.8 million; the TTM figure through Mar 2026 stood at $110.8 million (up 45.14% YoY), while the FY2025 annual figure was $101.5 million, up 541.65% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $110.8 million, up from $101.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $110.8 million in Q1 2026, with the low at $2.8 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $10.8 million (2022), against an average of $29.2 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 1477.37% in 2022, then tumbled 61.07% in 2023.
• Tarsus Pharmaceuticals' Accumulated Expenses stood at $9.9 million in 2022, then surged by 139.06% to $23.7 million in 2023, then sank by 33.21% to $15.8 million in 2024, then soared by 541.65% to $101.5 million in 2025, then gained by 9.18% to $110.8 million in 2026.
• Business Quant data shows TARS's Accumulated Expenses at $110.8 million in Q1 2026, $101.5 million in Q4 2025, and $13.6 million in Q3 2025.